AXGT News and Press, Axovant Gene Therapies Ltd. From 10/06/20

Gainers: Pioneer Power Solutions (PPSI) +323%.Ocean Power Technologies (OPTT) +82%.Electro-Sensors (ELSE) +30%.Asia Pacific Wire & Cable (APWC) +28%.Alteryx (AYX) +27%.Piedmont Lithium (PLL) +26%.ReneSola (SOL) +25%.TOMI Environmental Solutions (TOMZ) +25%TransAct Technolog...

Gainers: Kiniksa Pharmaceuticals (KNSA) +18%, Humanigen (HGEN) +15%, Neuronetics (STIM) +16%, American Well (AMWL) +13%, Xtant Medical (XTNT) +5%.Losers: Corbus Pharmaceuticals (CRBP) -39%, Axovant Gene Therapies (AXGT)-20%, Iovance Bioth...

Corbus Pharmaceuticals (CRBP) -31% as lenabasum flunks mid-stage cystic fibrosis study.Iovance Biotherapeutics (IOVA) -20% as it has not reached agreement with the FDA on the required potency assays to fully define its tumor-infiltrating lymphocyte therapy lifile...

Axovant Gene Therapies (AXGT) announces six-month follow-up data from the second cohort of Parkinson's disease ((PD)) patients who have received gene therapy AXO-Lenti-PD in the open-label, dose-escalation Phase 2 clinical trial, SUNRISE-PD.Two evaluable participants showed a 40% improvement ...

• AXO-Lenti-PD was well-tolerated with no treatment - related serious adverse events at 6 months • 2 1- point mean improvement i n UPDRS Part III “OFF” score, a 40 % improvement from baseline , e...

5 Biotech Penny Stocks To Watch Today Amid optimism around the President’s recovery and a pending stimulus plan, penny stocks are flying this morning. What has added more fuel to the fire is even bigger sector news. Earlier this morning, sympathy momentum started building...

NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the Company will present at upcoming conferences and will announce six-month safety and efficacy data from the second c...

If you're looking for under-the-radar stocks to buy, there's no better place to start your search than the biotech industry. Hardly a week goes by without at least one new biotechnology company going public. BridgeBio Pharma (NASDAQ: BBIO) is a member of the IPO class of 201...

Are Biotech Penny Stocks Part Of Your Strategy Right Now? This week, eyes are on things like energy penny stocks . That’s the case to kick off the Monday session. However, as traders try to chase the next big momentum breakout, smart money might be pivoting toward the “...

AXGT has promising gene therapy results in Parkinson's Disease. If future clinical results mimic the early ones, AXGT could have an addressable market of over $7.5 billion. Trading at an enterprise value of $143M, the risk reward ratio is enticing.  Nonetheless, investors sho...